Your browser doesn't support javascript.
loading
Whole genome sequencing identifies multiple loci for critical illness caused by COVID-19
Athanasios Kousathanas; Erola Pairo-Castineira; Konrad Rawlik; Alex Stuckey; Christopher A Odhams; Susan Walker; Clark D Russell; Tomas Malinauskas; Jonathan Millar; Katherine S Elliott; Fiona Griffiths; Wilna Oosthuyzen; Kirstie Morrice; Sean Keating; Bo Wang; Daniel Rhodes; Lucija Klaric; Marie Zechner; Nick Parkinson; Andrew D. Bretherick; Afshan Siddiq; Peter Goddard; Sally Donovan; David Maslove; Alistair Nichol; Malcolm G Semple; Tala Zainy; Fiona Maleady-Crowe; Linda Todd; Shahla Salehi; Julian Knight; Greg Elgar; Georgia Chan; Prabhu Arumugam; Tom A Fowler; Augusto Rendon; Manu Shankar-Hari; Charlotte Summers; Charles Hinds; Peter Horby; Danny McAuley; Hugh Montgomery; Peter J.M. Openshaw; Yang Wu; Jian Yang; Paul Elliott; Timothy Walsh; - GenoMICC Investigators; - 23andMe Investigators; - Covid-19 Human Genetics Initiative; Angie Fawkes; Lee Murphy; Kathy Rowan; Chris P Ponting; Veronique Vitart; James F Wilson; Richard H Scott; Sara Clohisey; Loukas Moutsianas; Andy Law; Mark J Caulfield; J. Kenneth Baillie.
Afiliação
  • Athanasios Kousathanas; Genomics England, London UK
  • Erola Pairo-Castineira; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Konrad Rawlik; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Alex Stuckey; Genomics England, London UK
  • Christopher A Odhams; Genomics England, London UK
  • Susan Walker; Genomics England, London UK
  • Clark D Russell; Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, UK
  • Tomas Malinauskas; Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK
  • Jonathan Millar; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Katherine S Elliott; Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK
  • Fiona Griffiths; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Wilna Oosthuyzen; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Kirstie Morrice; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.
  • Sean Keating; Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.
  • Bo Wang; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Daniel Rhodes; Genomics England, London UK
  • Lucija Klaric; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
  • Marie Zechner; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Nick Parkinson; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Andrew D. Bretherick; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
  • Afshan Siddiq; Genomics England, London UK
  • Peter Goddard; Genomics England, London UK
  • Sally Donovan; Genomics England, London UK
  • David Maslove; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.
  • Alistair Nichol; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland.
  • Malcolm G Semple; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L
  • Tala Zainy; Genomics England, London UK
  • Fiona Maleady-Crowe; Genomics England, London UK
  • Linda Todd; Genomics England, London UK
  • Shahla Salehi; Genomics England, London UK
  • Julian Knight; Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK
  • Greg Elgar; Genomics England, London UK
  • Georgia Chan; Genomics England, London UK
  • Prabhu Arumugam; Genomics England, London UK
  • Tom A Fowler; Genomics England, London UK
  • Augusto Rendon; Genomics England, London UK
  • Manu Shankar-Hari; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK.
  • Charlotte Summers; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Charles Hinds; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
  • Peter Horby; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.
  • Danny McAuley; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK
  • Hugh Montgomery; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.
  • Peter J.M. Openshaw; National Heart and Lung Institute, Imperial College London, London, UK
  • Yang Wu; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
  • Jian Yang; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang 310024, China
  • Paul Elliott; Imperial College, London
  • Timothy Walsh; Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.
  • - GenoMICC Investigators;
  • - 23andMe Investigators;
  • - Covid-19 Human Genetics Initiative;
  • Angie Fawkes; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.
  • Lee Murphy; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.
  • Kathy Rowan; Intensive Care National Audit & Research Centre, London, UK.
  • Chris P Ponting; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
  • Veronique Vitart; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.
  • James F Wilson; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, Teviot Place, Edinburgh EH8 9AG, UK.
  • Richard H Scott; Genomics England, London UK
  • Sara Clohisey; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Loukas Moutsianas; Genomics England, London UK
  • Andy Law; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.
  • Mark J Caulfield; Genomics England, London UK
  • J. Kenneth Baillie; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21262965
ABSTRACT
Critical illness in COVID-19 is caused by inflammatory lung injury, mediated by the host immune system. We and others have shown that host genetic variation influences the development of illness requiring critical care1 or hospitalisation2;3;4 following SARS-Co-V2 infection. The GenOMICC (Genetics of Mortality in Critical Care) study recruits critically-ill cases and compares their genomes with population controls in order to find underlying disease mechanisms. Here, we use whole genome sequencing and statistical fine mapping in 7,491 critically-ill cases compared with 48,400 population controls to discover and replicate 22 independent variants that significantly predispose to life-threatening COVID-19. We identify 15 new independent associations with critical COVID-19, including variants within genes involved in interferon signalling (IL10RB, PLSCR1), leucocyte differentiation (BCL11A), and blood type antigen secretor status (FUT2). Using transcriptome-wide association and colocalisation to infer the effect of gene expression on disease severity, we find evidence implicating expression of multiple genes, including reduced expression of a membrane flippase (ATP11A), and increased mucin expression (MUC1), in critical disease. We show that comparison between critically-ill cases and population controls is highly efficient for genetic association analysis and enables detection of therapeutically-relevant mechanisms of disease. Therapeutic predictions arising from these findings require testing in clinical trials.
Licença
cc_by_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
...